Pioglitazone improves measures of T2DM and dyslipidaemia

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1607, 2007-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pioglitazone improves BP, dyslipidaemia in diabetes

Inpharma, Vol. 1, Iss. 1497, 2005-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Pioglitazone Improves Diabetic Dyslipidaemia in Patients with Type 2 Diabetes Mellitus with or without Lipid-Lowering Therapy

By Schöfl Christof

Clinical Drug Investigation, Vol. 25, Iss. 5, 2005-01 ,pp. : 341-345

Adis International

Access to resources Recommend Favorite

Pioglitazone a star performer in the T2DM arena?

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Lower stroke and MI risk with pioglitazone in T2DM

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Pioglitazone economically attractive for type 2 DM in Canada

Inpharma, Vol. 1, Iss. 1331, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite